- Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
- Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
- Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
- Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
- Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022
Relmada Therapeutics Inc (RLMD:NSQ) closed at 4.12, 127.62% above the 52 week low of 1.81 set on Dec 08, 2022.
1.81Dec 08 202238.68Sep 30 2022
Markit short selling activity
|Market cap||124.01m USD|
|EPS (TTM)||-5.85 |
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.